Faron Pharmaceuticals Oy (LSE:FARN) Long-Term Capital Lease Obligation : £0.04 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Long-Term Capital Lease Obligation?

Faron Pharmaceuticals Oy's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.04 Mil.

Faron Pharmaceuticals Oy's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 (£0.14 Mil) to Jun. 2023 (£0.14 Mil) and declined from Jun. 2023 (£0.14 Mil) to Dec. 2023 (£0.04 Mil).

Faron Pharmaceuticals Oy's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (£0.01 Mil) to Dec. 2022 (£0.14 Mil) but then declined from Dec. 2022 (£0.14 Mil) to Dec. 2023 (£0.04 Mil).

Faron Pharmaceuticals Oy Long-Term Capital Lease Obligation Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Long-Term Capital Lease Obligation Chart

Faron Pharmaceuticals Oy Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.22

0.18

0.01

0.14

0.04

Faron Pharmaceuticals Oy Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.01	-	0.14	0.14	0.04

Faron Pharmaceuticals Oy (LSE:FARN) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Faron Pharmaceuticals Oy Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

FARON:Finland 4FR:Germany

Address

Joukahaisenkatu 6 B, Turku, FIN, 20520

Website

https://www.faron.com

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines